Targeted Decision Making In Renal Cell Carcinoma Relying on a Radiogenomics Translational Platform

Launched by IRCCS SAN RAFFAELE · Mar 4, 2025

Keywords

ClinConnect Summary

This clinical trial is designed to improve decision-making for patients with renal tumors, which are growths in the kidneys. The researchers will study how combining information from tumor samples and advanced imaging techniques like MRI can help doctors understand the tumor better. They aim to find specific markers that could indicate how well a patient might respond to different treatments, like medication or procedures that destroy the tumor.

To participate in this trial, individuals must be adults over 18 years old with a kidney mass measuring up to 4 centimeters. They should also be considered for kidney surgery and must agree to participate by signing an informed consent form. However, those who cannot undergo an MRI due to certain medical reasons will not be eligible. While the trial is not yet recruiting participants, it represents an exciting opportunity for those looking for advanced treatment strategies for kidney tumors.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Presence of a renal mass up to 4 cm
• • Adult \> 18 years
• • Candidate to renal surgery
• • Informed consent signed
• Exclusion Criteria:
• • Contraindication for MRI